Core Insights - Heartflow, Inc. is participating in a fireside chat at the Morgan Stanley Technology, Media & Telecom Conference on March 3, 2026, showcasing its leadership in AI technology for coronary artery disease [1] Company Overview - Heartflow is transforming coronary artery disease management, which is the leading cause of death globally, into a condition that can be detected early and managed effectively [4] - The Heartflow One platform utilizes AI to convert coronary CTA images into personalized 3D heart models, providing actionable insights into plaque characteristics and blood flow without invasive procedures [4] Technology and Research - Heartflow's technology is supported by the world's largest coronary imaging dataset, with over 160 million annotated CTA images, enabling advanced AI models that deliver accurate insights across diverse patient populations [5] - The company's AI-driven solutions have been validated through over 200 studies involving more than 365,000 patients, achieving coronary CTA image acceptance rates exceeding 97% [5] - Heartflow's solutions are backed by ACC/AHA guidelines and over 600 peer-reviewed publications, having redefined care management for over 500,000 patients worldwide [3][5] Commercial Presence - Heartflow has been adopted by more than 1,400 institutions globally, indicating a strong commercial presence and commitment to making its technology widely available [3] - The company ensures seamless clinical integration with upgraded workflows, providing quality-reviewed analyses instantly upon order, facilitating timely decision-making for clinicians [5]

NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, taking place virtually from February 25-26, 2026. Management, including Ben Zeskind, Chief Executive Officer, and Brett Hall, Chief Scientific Officer, will discuss the company’s pipeline, platform, and busines ...

SINGAPORE, Feb. 18, 2026 (GLOBE NEWSWIRE) -- RF Acquisition Corp III (the “Company”) today announced that it closed its initial public offering of up to 10,000,000 units at a price of $10.00 per unit on February 17, 2026. The units are listed on the Nasdaq Global Market (“Nasdaq”) and began trading under the ticker symbol “RFAMU” on February 13, 2026. Each unit consists of one ordinary share, par value $0.0001 per share, of the Company (“ordinary share”), and one right to receive one-tenth of one ordinary s ...

PERRYSBURG, Ohio, Feb. 18, 2026 (GLOBE NEWSWIRE) -- O-I Glass, Inc. (“O-I Glass” or “O-I”) today announced the Company will participate in BofA Securities 2026 Global Agriculture and Materials Conference on Wednesday, February 25, 2026. O-I Glass Chief Financial Officer John Haudrich will present at 10:30 a.m. ET. A live webcast of the presentation will be available at https://bofa.veracast.com/webcasts/bofa/globalagriculture2026/RnXq1t.cfm or can be accessed on the Company’s Investor Relations website, www ...

Core Insights - Nyxoah has signed a Memorandum of Understanding (MoU) with Sheikh Shakhbout Medical City (SSMC) to enhance Obstructive Sleep Apnea (OSA) therapy management and improve access to its Genio® therapy in the Middle East [1][2] Group 1: Partnership and Strategic Focus - The MoU aims to position SSMC as a leading regional center for Genio therapy, focusing on developing a high-volume implant program centered on patient care [2] - The collaboration includes establishing SSMC as a training hub for Genio therapy, educating surgeons, sleep physicians, and healthcare professionals across the region [3] Group 2: Clinical and Research Initiatives - Discussions are ongoing to explore clinical research and collaboration in sleep apnea and chronic disease management [3] - The initiative aligns with Nyxoah's vision to provide new treatment options for OSA patients and investigate the impact of advanced OSA management on chronic diseases like type 2 diabetes [4] Group 3: Company Overview and Product Information - Nyxoah specializes in developing innovative solutions for OSA, with its lead product being the Genio system, a leadless and battery-free hypoglossal neurostimulation therapy [5] - The Genio system received its European CE Mark in 2019 and has expanded its therapeutic indications following successful studies, including the BETTER SLEEP study and DREAM IDE pivotal study [6]

Core Viewpoint - CNB Financial Corporation's wholly-owned subsidiary, CNB Bank, has become a state member bank regulated by the Federal Reserve, marking a significant milestone in its strategic growth and enhancing its regulatory framework [1][2]. Group 1: Regulatory Changes - CNB Bank became a state member bank of the Federal Reserve System effective February 12, 2026, while continuing to be regulated by the Pennsylvania Department of Banking and Securities [1]. - The transition to a state member bank is expected to provide a more efficient supervisory process for CNB Bank [2]. Group 2: Company Overview - CNB Financial Corporation has consolidated assets of approximately $8.4 billion and operates primarily through CNB Bank, which offers a full range of banking services [3]. - CNB Bank has a diverse operational structure with 79 offices across Pennsylvania, Ohio, New York, and Virginia, including various divisions such as ERIEBANK, FCBank, and Impressia Bank [3].

Proposed amendment aims to lower management fees, reduce term and modify termination provision Louisville, Colorado, Feb. 18, 2026 (GLOBE NEWSWIRE) -- CEA Industries Inc. (Nasdaq: BNC) ("BNC" or the "Company"), a growth-oriented company focused on managing the world’s largest corporate treasury of BNB, today announced that BNC’s Board of Directors (the “Board”) has made a proposal to 10X Capital Asset Management LLC ("10X") to amend the Company's Asset Management Agreement (the "AMA"). Among other enhanceme ...

HAMILTON, Bermuda, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Teekay Tankers Ltd. (Teekay Tankers or the Company) (NYSE: TNK) today reported the Company's results for the three months and year ended December 31, 2025, and announced that its Board of Directors has declared its regular, fixed quarterly cash dividend of $0.25 per share for the quarter ended December 31, 2025. The cash dividend is payable on March 13, 2026 to all shareholders of record as at March 2, 2026. The full earnings release and Teekay Group’s ea ...

Core Insights - Medallion Financial Corp. reported record financial results for 2025, with significant increases in net interest income, net income, loan originations, and portfolio size, indicating strong operational performance and demand across its business segments [4][7]. 2025 Fourth Quarter Highlights - Total net income for Q4 2025 was $12.2 million, or $0.50 per share, a 20% increase from $10.1 million, or $0.43 per share in Q4 2024 [7]. - Net interest income rose 8% to $56.4 million from $52.0 million in the prior year quarter [7]. - Loan originations increased to $421.3 million, compared to $285.7 million in the prior year quarter, with strategic partnership loan originations contributing $258.3 million [7]. 2025 Full-Year Highlights - Total net income for 2025 was $43.0 million, or $1.78 per share, up 20% from $35.9 million, or $1.52 per share in 2024 [7]. - Net interest income grew 7% to $216.9 million from $202.5 million in the prior year [7]. - Loan originations for the year reached $1.505 billion, compared to $1.043 billion in 2024, with strategic partnership loan originations totaling $771.6 million [7]. Executive Commentary - The President and CEO highlighted the company's disciplined origination strategy and effective capital deployment, positioning it for continued growth and favorable risk-adjusted returns for shareholders [4][5]. 2026 Strategy - The company aims to focus on sustained growth in its recreation segment and explore growth potential in home improvement lending, supported by experienced talent [6]. Loan Portfolio Composition - As of December 31, 2025, the loan portfolio included $1.617 billion in recreation loans (63% of total loans), $810.2 million in home improvement loans (32%), and $123.1 million in commercial loans (5%) [16]. - The total loans and loans held for sale amounted to $2.566 billion, up from $2.491 billion a year ago [16]. Capital Allocation - The company declared a quarterly cash dividend of $0.12 per share, payable on March 31, 2026 [18][19]. - During 2025, the company repurchased 108,351 shares at an average cost of $9.10 per share, totaling $1.0 million [23]. Financial Position - As of December 31, 2025, total assets were $2.955 billion, an increase from $2.869 billion in 2024, while total liabilities rose to $2.447 billion from $2.430 billion [22].

MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025, after the market close on Wednesday, March 4, 2026. The Company’s management will discuss the results during a ...